Experimental panic provocation in healthy man—a translational role in anti-panic drug development? by Kellner, Michael
Experimental provocation of panic 
attacks in panic disorder patients
anic attacks are defined as sudden and short-
lived anxiety spells with various somatic and cognitive
symptoms. According to DSM-IV, these discrete periods
of intense fear or discomfort develop abruptly and reach
a peak within 10 minutes. Furthermore, at least four of
the following thirteen symptoms evolve: palpitations or
accelerated heart rate; sweating, trembling, or shaking;
sensations of shortness of breath or smothering; feeling
of choking, chest pain, or discomfort; nausea or abdom-
inal distress; feeling dizzy, unsteady, lightheaded, or faint;
derealization or depersonalization; fear of losing control
or going crazy; fear of dying; paresthesias; chills or hot
flashes. Panic attacks can occur sporadically in healthy
man, but also in the context of anxiety disorders (if the
panic attacks are not due to the direct physiological
effect of a substance or a general medical condition).
Diagnostically, recurrent panic attacks are the hallmark
of panic disorder, which is a disabling anxiety disorder
that has a lifetime prevalence of about 5%.
1
The interest in the neurobiology of panic attacks has
considerably been stimulated by the discovery that these
spontaneous anxiety paroxysms can be provoked exper-
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Experimental neurochemical provocation of panic attacks
in susceptible human subjects has considerably expanded
our knowledge of the pathophysiology and psychophar-
macology of panic disorder. Some panicogens also elicit
short-lived panic-like states in healthy man. This offers the
opportunity to assess the anti-panic action of drugs in
proof-of-concept studies. However, from current data it is
still unclear whether experimental panic in healthy man
is a valid translational model. Most such studies in healthy
volunteers have been performed using a cholecystokinin
tetrapeptide (CCK-4) challenge. While CCK-4 panic was
blocked by alprazolam pretreatment, escitalopram
showed negative results in healthy man. Preliminary find-
ings on novel investigational drugs and a few problematic
results will be reviewed. Small sample sizes in many panic
provocation studies, lack of dose-response aspects, and
still-insufficient knowledge about the biological under-
pinning of experimental and spontaneous panic limit the
interpretation of existing findings and should inspire fur-
ther research.   
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controlled conditions. The seminal report about neuro-
chemical provocation of panic attacks in man was pub-
lished by Pitts and McClure in 1967.
2 Based on the
observation that patients with “anxiety neurosis” were
exercise-intolerant and developed high blood levels of
lactic acid during standardized workload, these
researchers developed the idea that the lactate molecule
might be the elicitor of anxiety attacks in vulnerable
individuals. In a double-blind study with intravenous
infusion of 10 mL/kg body weight of 0.5 molar sodium
lactate over a maximum of 20 minutes, 13 out of 14
patients with anxiety neurosis (all of them with a history
of spontaneous anxiety spells), but only 2 out of 10
healthy controls, developed typical anxiety attacks. This
observation laid the foundation for extensive research
efforts on the experimental psychopathology of panic,
which offers a unique opportunity in the field of psychi-
atry. 
The scientific and clinical promises of such symptom
provocation studies for the pathophysiology and psy-
chopharmacology of psychiatric disorders have been
drafted as follows
3: 
In this paradigm investigators administer a psychopharma-
cologic agent or psychological challenge procedure to
patients under controlled conditions to probe psychiatric
symptoms and other neurobiological responses. The princi-
ple scientific rationale behind this approach is to learn more
about the underlying pathophysiological mechanisms
responsible for the symptomatic expression of psychiatric ill-
nesses. In addition, the knowledge gained from this type of
study might lead to better predictors of treatment response
or identification of novel therapeutic interventions.
A quintessential ethical framework of challenge stud-
ies includes preserved decision-making capacity,
informed consent, potential scientific and future clini-
cal benefits, consent of an ethical committee, a favor-
able or acceptable risk:benefit ratio, absence of severe
or long-lasting effects of the challenge agent, and fol-
low-up studies on the effects of participation in symp-
tom-provoking studies.
In addition to lactate infusion, several further methods to
provoke experimental panic attacks in patients with panic
disorder by pharmacological means have been developed
during the past decades (overview in ref 4). These display
many different modes of action and have different targets.
They include other agents that influence respiration, such
as carbon dioxide inhalation or doxapram infusion.
Further established panicogens act specifically on neuro-
transmission, such as the noradrenergic substances yohim-
bine and isoprenaline, the serotonergic agents meta-
chlorophenylpiperazine (mCPP) and fenfluramine,
benzodiazepine-receptor agents, such as the inverse ago-
nist FG 7142 and the antagonist flumazenil, agonists at the
CCK-2 (formerly type B) receptor, such as cholecys-
tokinin tetrapeptide (CKK-4) and pentagastrin, and the
adenosine receptor antagonist caffeine. 
The following criteria for an ideal panicogen for human
use have been proposed (compiled according to
Gutmacher et al
5 and Gorman et al
6):
￿ It should be safe
￿ It should mimic naturally occurring panic attacks
￿ It should foster both central and peripheral manifes-
tations of panic
￿ It should be replicable
￿ The phenomena should be either short-lived or read-
ily reversible
￿ It should differentiate between healthy subjects and
those with pathology
￿ It should reflect the potential for a state response;
those who have been successfully treated clinically
should not respond or respond far less than those who
have had no treatment
￿ The effects should not be blocked by drugs, which do
not work against spontaneous panic.
Concerning the claimed “potential for a state response”
in patients after successful anti-panic treatment, the fur-
ther discourse of this paper will be restricted to drug
treatment (and will not address findings after psy-
chotherapeutic treatment or spontaneous remission).
Pharmacological modulation of experimental
panic in panic disorder patients
The use of experimental panic provocation by panico-
gens after psychopharmacological anti-panic treatment
may be a more advantageous means to assess drug
effects than just waiting for days and weeks for sponta-
neous panic attacks to occur, and having the patients
keep panic diaries to characterize panic frequency and
severity. In some regard, this procedure resembles the
role of the well-known exercise stress test in diagnosis
and treatment of angina pectoris in internal medicine.
Several studies, mostly with lactate, carbon dioxide, or
CCK-4, have demonstrated that the established anti-
panic drug treatments with nonselective serotonin reup-
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take inhibitors (the tricylic antidepressants imipramine
and clomipramine), various selective serotonin reuptake
inhibitors (SSRIs) and benzodiazepines (particularly
alprazolam) indeed diminish experimentally induced
panic in patients with panic disorder.
In detail, in studies with sodium lactate infusions prior
medication with the benzodiazepines diazepam
7,8 and
alprazolam
9-11 as well as with the tricyclic antidepressant
imipramine
8,12,13 significantly decreased induction of panic
anxiety in panic patients and thus appeared to increase
the threshold for lactate-induced panic attacks. Carbon
dioxide (35%)-induced panic was attenuated in panic
disorder patients after treatment with the benzodi-
azepines clonazepam
14,15 and alprazolam,
16 with
imipramine or clomipramine,
17-19 paroxetine, sertraline,
or fluvoxamine.
18-20 CCK-4-elicited panic was decreased
in panic patients after imipramine treatment
21 and after
citalopram or fluvoxamine.
22,23 The response to the fur-
ther panicogens after treatment with standard anti-panic
drugs are less intensively studied in patients—alprazo-
lam blocked the panic symptoms provoked by mCPP
(piperazine)
24 and yohimbine,
25 long-term imipramine
did not alter yohimbine-induced increases in ratings of
anxiety-nervousness,
26 but fluvoxamine reduced yohim-
bine-induced anxiety.
27
For some investigational drugs experimental panic provo-
cation has been used in patients with panic disorder (with-
out prior testing in panic models in healthy man, as
described in the following paragraphs). The emerging data
might give valuable information for decision making as to
whether further study on their action on spontaneous
attacks is worthwhile. However, a definite evaluation of
the informative value of this approach at this stage is not
yet possible due to the paucity of studies.
A single oral dose of 50 mg of L-365,260, a central CCK
receptor antagonist, had shown a differential action on
CCK-4- and lactate-induced panic attacks in patients
with panic disorder. In a double-blind, placebo-con-
trolled, crossover study in 29 patients, CCK-4 90 minutes
after L-365,260 significantly reduced the number and
sum intensity of provoked panic symptoms.
28 In contrast,
a double-blind, placebo-controlled parallel-group study
in 24 patients with sodium lactate infusion given after
the same dosage of the compound and in the identical
time frame failed to reveal statistical differences on
these panic attack parameters.
29 In a multicenter,
placebo-controlled, double-blind trial with L-365,260 30
mg qid for 6 weeks no clinically significant treatment
effects in panic attack frequency or intensity were found
and testing higher doses was suggested,
30 but has not
been performed so far. 
In a double-blind, placebo-controlled, crossover design,
nine panic patients were given an intravenous infusion
of 150 µg of atrial natriuretic peptide (ANP) followed by
experimental panic induction using CCK-4.
31 The ratio-
nale was derived from observations that ANP is released
during panic attacks in humans and has anxiolytic-like
effects in preclinical studies.
32 The CCK-4 response as
per Acute Panic Inventory (API) ratings was signifi-
cantly reduced after ANP versus placebo pretreatment.
These findings of anti-panic activity of ANP were repli-
cated in another study in ten panic patients under com-
parable experimental conditions with a lower dose of
CCK-4.
33 Unfortunately, until now no study about the
action of ANP (or another agonist at the type A natri-
uretic peptide receptor) on spontaneous panic attacks in
patients with panic disorder has been reported.
An early study in outpatients suffering from panic dis-
order using the panic response to CCK-4 challenge as
the primary outcome parameter was conducted with the
novel neurokinin-3 (NK-3) receptor antagonist
SR142801 (osanetant).
34 Fifty-two patients who had
developed a panic attack with CCK-4 were randomized
to 4 weeks of treatment (200 mg/d orally) in a double-
blind, placebo-controlled design and then a second
CCK-4 challenge was performed. However, with regard
to the primary efficacy end point, ie, the increase of API
total score, osanetant was not significantly different from
placebo. On the Panic and Agoraphobia Scale no signif-
icant treatment effects of this compound were detected
during these 4 weeks.
Experimental provocation of panic 
attacks in healthy volunteers
For many panic patients it is quite aversive and fright-
ening to undergo an experimental panic challenge and
to be treated with an investigational product due to cat-
astrophizing disorder-immanent cognitions, fears of side
effects, and the possibility of being randomized to
placebo treatment. To bridge the gap between preclini-
cal panic models
35 and studies in patients, experimental
panic provocation in healthy human subjects might serve
as a valuable tool for assessment of novel anti-panic
compounds during the early phase of drug development
in proof-of-concept studies. Healthy volunteer transla-
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tional studies might deliver valuable information on
whether it is worthwhile to consider further, more thor-
ough studies in patients.
However, standard sodium lactate panic is not an apt
panic model in healthy subjects, because, as already men-
tioned, in contrast to patients with panic disorder, only a
small percentage of healthy humans develop panic symp-
toms to it. Interestingly, Sinha et al
36 investigated, in a sin-
gle-blind pilot study, whether additional pretreatment
with naloxone, an opioid receptor antagonist, could ren-
der healthy controls who are nonresponsive to panic
induction by lactate infusion sensitive to the latter pan-
icogen. Indeed, substantial increases in the API scores
were displayed by 8 out of 12 subjects during such treat-
ment; naloxone alone did not result in panic symptoms.
In a following more sophisticated investigation in 25 vol-
unteers (using a crossover, randomized design) further
evidence was shown that impairment of the endogenous
opioid system by naloxone accentuates symptomatic
response to lactate, but no significant differences in API
ratings were detected.
37 Notwithstanding, the authors sug-
gest testing the specificity of the naloxone-lactate model
in healthy man comparing specific anti-panic medications
with ineffective anti-panic agents, and furthermore
screening for putative anti-panic agents with this method.
Further studies will demonstrate whether this complex
model is applicable for translational panic research in
healthy humans.
Panic provocation in healthy volunteers is more feasible
using CCK-4 or carbon dioxide. The further discourse
will be restricted to these two panicogens, because we are
not aware of any published studies testing anti-panic
drugs in normal volunteer challenge studies using other
substances. Although patients with panic disorder show
an enhanced sensitivity to intravenous bolus injection of
CCK-4, increasing its dose brings about a substantial
panic-like reaction also in normal controls. While the
panic rate after injection of 25 µg was 91% for patients
and only 17% for controls, 50 µg of CCK-4 induced a full-
blown panic attack in 100% of patients and in a sizable
47% of controls.
38Among healthy volunteers significant
dose-related differences were also found for the number
of panic symptoms and their sum intensity,
39 which makes
CCK-4 a useful research model for dimensional aspects
of panic also in the nonclinical subjects who do not
develop a full-blown panic attack.
40 Also, with a single
breath of 35% carbon dioxide inhalation panic patients
show significantly stronger symptoms of panic anxiety
than normal controls.
41,42The induced cluster of symptoms
in healthy volunteers is, however, similar to those elicited
in panic attacks naturally occurring in patients affected
by panic disorder.
43 But the panic signal obtained with
one breath of 35% carbon dioxide seems to be weaker
than with injection of 50 µg of CCK-4 in healthy subjects:
Direct comparison of only 25 µg of CCK-4 and 35% car-
bon dioxide revealed significantly more intense symp-
toms with CCK-4, but not a significantly greater number
of symptoms; the incidence of panic attacks was similar:
21% for CO2 and 17% for 25 mg of CCK-4.
44
A methodological problem is that psychometric assess-
ment of induced panic does not follow consistent rules –
different panic rating scales, such as the API and the
DSM-derived Panic Symptom Scale (PSS) are used and
different criteria to divide panickers from non-panick-
ers. To provide a basis for the use of the CCK-4 model
in proof of concept studies in healthy volunteers, the psy-
chometric, cardiovascular, and neuroendocrine
responses to 50 µg of CCK-4 were studied in 85 healthy
men.
45 The API-derived panic rate was 78.8% and thus
10.6% higher than that derived from the PSS ratings
(68.2%). This should be taken into account when com-
paring studies and when choosing a categorical instead
of a dimensional outcome parameter of panic provoca-
tion. Another result of this study was that cardiovascu-
lar and hormonal alterations to CCK-4 challenge are not
valuable as an objective readout of panic. We must bear
in mind to depend on relatively “weak” data from self-
report when assessing panic anxiety.
Pharmacological modulation of 
experimental panic in healthy volunteers
Because the vast majority of studies on pharmacological
modulation of experimental panic in healthy volunteers
was performed using CCK-4, the focus here will be on
this panicogen (for synopsis of results, please see Table
I). In the 35% carbon dioxide model of panic in healthy
volunteers an acute dose of 1 mg alprazolam 2 hours
before inhalation resulted in significant anti-panic effects
in a double-blind, placebo-controlled, three-way
crossover study in 12 healthy subjects.
46 With an SSRI,
only one study in healthy man using the 35% CO2 chal-
lenge has been published.
47 In this 2-week double-blind,
placebo-controlled trial in 24 subjects, who were at high
risk for panic disorder because of a personal history of
panic attacks or a family history of treated panic disor-
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bon dioxide testing, 10 mg/d of escitalopram failed to
affect experimental panic. However, the caveat must be
applied that time of treatment with an SSRI of only 14
days might not be long enough to manifest anti-panic
action, because clinical benefits for SSRI in panic disor-
der typically take longer. Further studies must clarify,
whether the 35% carbon dioxide panic model is sensitive
to modulation with serotonergic antidepressants and
other anti-panic drugs in healthy man.
Established anti-panic drugs and CCK-4 panic in
healthy volunteers
The acute inhibitory effect of benzodiazepines on CCK-
4 panic in normal man has been demonstrated in two
studies. In an early, small exploratory open-label study
De Montigny
48 showed that pretreatment with
lorazepam (1 mg at 4 PM and 2 mg at bedtime on the
preceeding day, 1 mg at 8 AM 1 hour before CCK-4
challenge) prevented the psychic effects of CCK-4
(doses between 75 and 150 µg) in four subjects who had
experienced a panic-like attack with the same dose of
this peptide before. In a double-blind, placebo-con-
trolled, parallel-group study in 30 healthy volunteers
treated with 1 mg alprazolam 1 hour prior to a 50-µg
CCK-4 challenge, a significant reduction of API and PSS
scores and of the number of reported symptoms com-
pared to placebo pretreatment were found.
49 A recent
study (following an unbalanced, three-arm, two-period,
crossover, double-blind, placebo-controlled design) in 21
male volunteers who received 1 mg of lorazepam 2
hours before CCK-4 did not show an attenuated panic
signal in any PSS parameter.
50 However, this dose of
lorazepam was considerably lower than in the two pre-
vious studies reported above.
Concerning anti-panic non-selective serotonin reuptake
inhibitors (imipramine or clomipramine) no study on
CCK-4 panic in healthy volunteers has been published.
With an SSRI, Kellner et al
51 could not demonstrate an
inhibitory effect of escitalopram (6 weeks of 10 mg/d) on
a 50-µg CCK-4 challenge in a double-blind, placebo-con-
trolled, randomized, within-subject crossover design in
30 healthy young men. Induced panic under escitalo-
pram was even significantly more pronounced in the
subgroup of subjects with the short/short genotype for
the serotonin transporter linked polymorphic region in
this study. Another investigation with an identical dose
and duration of escitalopram pretreatment also failed to
show a significant inhibitory effect on CCK-4 panic in
healthy man (I. Tõru, personal communication).
Investigational anti-panic drugs and CCK-4 panic in
healthy volunteers
To test the effectiveness of a single oral 100 mg dose of
the cholecystokinin B antagonist CI-988 in attenuating
panic symptoms induced by CCK-4 a randomized,
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Healthy man: CCK-4 Panic disorder patient: CCK-4 Panic disorder patient: diary
Established antipanic drugs
Imipramine ? (+) +
Selective serotonin reuptake inhibitors 0 + +
Alprazolam + ? +
Investigational antipanic drugs
CCK-B antagonist CI-988 + 0 0
CCK-B antagonist L-365,260 ? + 0
mGlu 2/3 agonist LY544344 (+) ? ?
Atrial natriuretic peptide 0 + ?
NK-3 antagonist SR142801 ? 0 0
β−blocker propranolol (+) ? 0
GABA reuptake inhibitor tiagabine (+) (+) 0
GABA transaminase inhibitor vigabatrine (+) ? ?
Translocator protein (18 kD) ligand XBD173 + ? ?
Table I. Cholecystokinin-tetrapeptide (CCK-4)-induced panic in humans – inhibition of panic symptoms by drug pretreatment? +, evidence for inhi-
bition of panic as per a double-blind, placebo-controlled study, (+), limited evidence for inhibition of panic; 0, no inhibition of panic observed;
?, no study published; mGlu, metabotropic glutamate; NK-3, neurokinin 3; GABA, γ-aminobutyric acid
PAGES_12_AG_1005_BA.qxd:DCNS#51  1/12/11  14:54  Page 489placebo-controlled, double-blind, three-way crossover
design was used in 30 healthy men.
52A small (14%), but
significant decrease of sum intensity scores of panic
symptoms was observed under CI-988. However, there
was no marked difference in the number of panic symp-
toms. In contrast, a subsequent study in 14 patients with
panic disorder who were given 50 or 100 mg of CI-988 in
a double-blind, two-period incomplete block design 2
hours before injection of CCK-4 failed to show a statis-
tically significant treatment effect on the total intensity
score on the PSS (the primary efficacy parameter), as
well as on the number of panic symptoms, time to and
occurrence of the first panic symptoms, duration of
symptoms, intensity of apprehension, and the percent-
age of patients who did not have a panic attack.
53 In a
randomized, double-blind, placebo-controlled trial with
100 mg tid of CI-988 in panic patients no superiority to
placebo in reducing panic attacks could be shown.
54
After the metabotropic glutamate 2/3 receptor agonist
LY544344/LY354740 had shown acute anxiolytic-like
action in preclinical studies, a pilot study on panic anxi-
ety induced by CCK-4 was performed in healthy
humans.
55 Twelve male volunteers were treated with 80
mg bid LY544344 orally for 1 week in a randomized
placebo-controlled double-blind crossover design. While
no significant treatment effect for the number of CCK-4-
induced panic symptoms and subjective anxiety ratings
emerged in the entire sample, the ten subjects who
showed an endocrine response to the test substance dis-
played a significant reduction on these two measures.
Unfortunately, due to emerging problems in long-term
preclinical safety, no subsequent clinical studies were
performed with this compound.
The finding of a significant anti-panic effect of atrial
natriuretic peptide (ANP) in patients with panic disor-
der has already been mentioned above.
31 In this double-
blind, placebo-controlled, crossover study also nine
healthy control subjects matched for sex and age were
included and they were given an intravenous infusion of
150 µg of ANP followed by CCK-4 panic induction.
However, no significant treatment effect of ANP on API
ratings was observed in healthy man.
The  β-blocker propranolol (0.2 mg/kg given intra-
venously over 20 minutes) has been observed to signifi-
cantly decrease the CCK-4 response (sum intensity and
number of panic symptoms) in a study in 30 healthy
male volunteers who were randomly assigned to pro-
pranolol or placebo.
56 In panic patients no study with a
β-blocker has been reported using the CCK-4 model and
in a 5-week double-blind placebo-controlled study, no
efficacy of propranolol on spontaneous attacks was
detected.
57 Interestingly, using the CCK-B receptor ago-
nist pentagastrin for panic provocation in a double-blind,
randomized, placebo-controlled study with identical
dose and application of propranolol as above in a pre-
dominantly female group of 16 healthy adult subjects, no
significant effect on total symptom intensity as per the
API was observed.
58
Regarding GABA (γ-aminobutyric)-ergic drugs other
than benzodiazepines both the GABA reuptake inhibitor
tiagabine and the GABA transaminase inhibitor vigaba-
trin have been studied in this experimental panic para-
digm. Fifteen healthy volunteers received 15 mg
tiagabine daily for 1 week in an open study. Both API-
and PSS-scores showed a significant reduction to a CCK-
4 stimulus that was performed before and after treat-
ment.
59 In a following double-blind placebo-controlled
pilot study with 4 weeks of tiagabine in 19 patients with
panic disorder a subset of seven patients (three treated
with tiagabine, four treated with placebo) was challenged
with 25 µg of CCK-4 at baseline and after 14 and 28
days.
60 Patients of the tiagabine vs the placebo group
showed considerably decreased sensitivity to CCK-4 (as
per API ratings). However, clinical benefits of tiagabine
on the Panic and Agoraphobia Scale were not detected.
Also a 10-week open study suggested that tiagabine may
be of little benefit on this measure.
61
Vigabatrine (2 mg/d) was given for 7 days to ten healthy
volunteers in an open-label study after placebo-con-
trolled administration of CCK-4 and a second CCK-4
challenge followed after the treatment period.
62 A
marked and significant attenuation of CCK-4 induced
panic symptoms (as per API and PSS scores) and of anx-
iety was observed with vigabatrine. However, no
placebo-controlled and double-blind study has followed
so far and the effect of vigabatrine has not been investi-
gated in the CCK-4 paradigm in panic patients. Current
data on the clinical efficacy of vigabatrine in panic
patients are still casuistic.
63
Recently, the translocator protein (18 kD) ligand
XBD173, which enhances GABAergic neurotransmis-
sion via induction of neurosteroidogenesis, was tested in
71 healthy male volunteers who had shown a clear panic
response to an initial CCK-4 challenge.
64 In this double-
blind study the subjects were randomized to 7 days of
treatment with placebo, 10, 30, or 90 mg/day of XBD173
490
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or 2 mg/d alprazolam as active control condition. A sig-
nificant difference from placebo in the difference of the
API ratings between the first and the second challenge
(on day 7) with CCK-4 was found for alprazolam and
the highest dose of XBD173. Studies in panic patients
with this compound are being awaited.
Conclusions
Despite ample exciting research efforts, we are still far
from having reliable information on model validity of
experimental panic provocation paradigms in healthy
man as tools to test novel anti-panic drugs. A few false-
negative or false-positive findings question the useful-
ness of this approach. Existing preliminary data need
replication using exclusively double-blind, placebo-con-
trolled designs. Comparability of results is hampered by
different psychometric methods applied. Especially for
multicenter trials, standardization of the test environ-
ment and subjects’ instruction need careful attention.
Many findings were obtained with relatively small sam-
ples and few studies had included women. Rarely have
dose-response aspects been investigated. Challenge stud-
ies with genetically precharacterized and homogenized
samples are worth considering and may achieve clearer
results.
65 Another problem is that our growing under-
standing of the complex pathophysiology of panic sug-
gests that there may be no unitary model but possibly
different phenocopies, leading to a similar pathophysio-
logical phenomenon. Hopefully, further research will
eventually lead us to more definite knowledge on which
panicogens in healthy man are capable of predicting the
usefulness of various anti-panic drugs for treatment in
panic disorder.  ❏
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hombres sanos: ¿un procedimiento 
traslacional para el desarrollo de fármacos
antipánico?
La provocación neuroquímica experimental de ataques de
pánico en seres humanos susceptibles ha ampliado con-
siderablemente nuestro conocimiento acerca de la fisiopa-
tología y psicofarmacología del trastorno de pánico.
Algunos agentes panicogénicos también provocan estados
tipo pánico de corta duración en hombres sanos. Esto
ofrece la oportunidad de evaluar la acción antipático de
fármacos en estudios de prueba de concepto. Sin embargo,
a partir de la información actual aun no está claro si el
pánico experimental en hombres sanos es un modelo
traslacional válido. La mayoría de los estudios en volun-
tarios sanos se han efectuado empleando la provocación
con el tetrapéptido colecistoquinina (CCK-4). En hombres
sanos el pánico con CCK-4 fue bloqueado al pretratar con
alprazolam, efecto que no se consiguió con escitalopram.
Se revisan los hallazgos preliminares de nuevos fármacos
de investigación y algunos resultados controvertidos. La
interpretación de los hallazgos existentes está limitada por
el pequeño tamaño de las muestras en muchos estudios de
provocación, la falta de investigación en los aspectos dosis-
respuesta y el conocimiento aun insuficiente sobre los fun-
damentos biológicos del pánico experimental y espontá-
neo, por lo que es necesario promover futuros estudios.   
Provocation expérimentale de la panique
chez l’homme sain, un rôle translationnel
dans le développement de médicaments
antipanique ?
La provocation neurochimique expérimentale d’attaques
de panique chez les sujets humains sensibles a considéra-
blement enrichi notre connaissance de la physiopathologie
et de la psychopharmacologie des troubles paniques.
Certains produits induisant la panique provoquent des états
de panique de courte durée chez des hommes sains, ce qui
offre l’opportunité d’évaluer le pouvoir antipanique des
médicaments dans des études de faisabilité. Cependant, les
données actuelles ne permettent pas de savoir si la panique
expérimentale chez l’homme sain est un modèle transla-
tionnel valable. La plupart de ces études chez des volon-
taires sains ont été réalisées grâce à l’aide d’un tétrapep-
tide de cholécystokinine (CCK-4). Alors que la panique
provoquée par le CCK-4 a été bloquée par un prétraitement
par l’alprazolam, l’escitalopram a donné des résultats néga-
tifs chez l’homme sain. Des résultats préliminaires concer-
nant des nouveaux produits en développement seront dis-
cutés ainsi que quelques résultats problématiques. Les petits
échantillons de nombreuses études de provocation de la
panique, le manque de visibilité sur la réponse selon la dose
et la connaissance encore insuffisante des bases biologiques
de la panique expérimentale et spontanée limitent l’inter-
prétation des résultats existants, et devraient conduire à la
réalisation de nouvelles recherches. 
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